This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Short Report and Other Explanations For Gilead Sciences' Sell Off

By: Adam Feuerstein | 02/05/14 - 10:54 AM EST

Gilead Sciences (GILD) is down 5% to $77.70 Wednesday following what seemed like strong fourth-quarter earnings and an optimistic outlook for 2014 (despite excluding hepatitis C drug sales from revenue guidance.)

So, why the hell is the stock so weak? 

I have no definitive answer, of course. The broader market is selling off today and biotech stocks are particularly weak. 

Favus Institutional Research, Elliot Favus' proprietary research shop, issued a short report on Gilead today, offering seven reasons to sell the stock -- none of which are really new. To summarize, Favus says Gilead is heading lower because 1) there is little margin of error for the Hep C drug launch with expectations already sky high; 2) Gilead's shareholder base has become too generalized and they don't understand Hep C; 3) Gilead admission that it will run DTC ads for Hep C is a negative; 4) Hep C is not like HIV because patients are cured; 5) Abbvie (ABBV) is competitive; 6) Lots of Hep C patients are veterans and/or prisoners, making access and pricing challenging; 7) the retirement of Gilead's commercial operations chief Kevin Young is weird. 

Has anyone not heard these arguments before? Doesn't necessarily mean some/all are not true, but it's not like Favus has uncovered the big smoking gun that will take down Gilead, either. 

Anyone else want to take a shot at explaining Gilead's weakness? Mark Schoenebaum of ISI Group, I see your hand raised. Take a stab:

1) Gilead's decision not to give Hep C product sales guidance last night is worrying investors, even though the company is known to be conservative. 2) The [favorable] tax comments on the conference call were confusing. 3) Operating expense guidance for 2014 was higher than anticipated. 4) Gilead has changed its tune about who is taking Sovaldi. It's now more genotype 1s than genotype 2s, which could suggest an increased risk of a sales slowdown later this year before the Sovaldi/ledispavir launch. 

And what does this all mean, Mr. Schoenebaum?

The critical point with stock is, in my opinion, that GILD is virtually assured of earning at least $8, and probably closer to $10 by 2016. Thus, at around $80, the implied PE on that number is not high and downside seems pretty limited. And, if they crush Street numbers and investors can get incremental comfort that there is "tail value" here (this is the BIGGEST INVESTOR DEBATE RIGHT NOW!!), a PE of around 12x 2016 (i.e. $95-$100) seems doable when we are standing in January of 2015.

Thank you. 


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 17,071.22 -41.93 -0.24%
S&P 500 1,977.80 -5.05 -0.25%
NASDAQ 4,505.8520 -6.3420 -0.14%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs